The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 12, 2005

Filed:

May. 05, 2000
Applicants:

Peter J. Sims, Mequon, WI (US);

Alfred L. M. Bothwell, Guilford, CT (US);

Eileen A. Elliot, New Haven, CT (US);

Richard A. Flavell, Killingworth, CT (US);

Joseph Madri, North Branford, CT (US);

Scott Rollins, Monroe, CT (US);

Leonard Bell, Woodbridge, CT (US);

Stephen Squinto, Irvington, NY (US);

Inventors:

Peter J. Sims, Mequon, WI (US);

Alfred L. M. Bothwell, Guilford, CT (US);

Eileen A. Elliot, New Haven, CT (US);

Richard A. Flavell, Killingworth, CT (US);

Joseph Madri, North Branford, CT (US);

Scott Rollins, Monroe, CT (US);

Leonard Bell, Woodbridge, CT (US);

Stephen Squinto, Irvington, NY (US);

Assignees:

Oklahoma Medical Research Foundation, Oklahoma City, OK (US);

Yale University, New Haven, CT (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N005/10 ; C12N015/63 ; A61K048/00 ; A01N067/027 ;
U.S. Cl.
CPC ...
Abstract

Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i.e., hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.


Find Patent Forward Citations

Loading…